Cargando…

Genome-Wide Analyses of Prognostic and Therapeutic Alternative Splicing Signatures in Bladder Urothelial Carcinoma

BACKGROUND: Alternative splicing (AS) is an indispensable post-transcriptional modification applied during the maturation of mRNA, and AS defects have been associated with many cancers. This study was designed to thoroughly analyze AS events in bladder urothelial carcinoma (BLCA) at the genome-wide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Zhongru, Zhang, Zhe, Piao, Chiyuan, Liu, Zhuona, Wang, Zeshu, Kong, Chuize
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033158/ https://www.ncbi.nlm.nih.gov/pubmed/33842332 http://dx.doi.org/10.3389/fonc.2021.626858

Ejemplares similares

Genome-Wide Profiling of Prognostic Alternative Splicing Signature in Colorectal Cancer
por: Zong, Zhen, et al.
Publicado: (2018)

Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma
por: Yang, Chengkun, et al.
Publicado: (2019)

Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma
por: Xu, Chaojie, et al.
Publicado: (2022)

Prognostic Signatures of Alternative Splicing Events in Esophageal Carcinoma Based on TCGA Splice-Seq Data
por: Ye, Ping, et al.
Publicado: (2021)

Overexpression of UNC5B in bladder cancer cells inhibits proliferation and reduces the volume of transplantation tumors in nude mice
por: Kong, Chuize, et al.
Publicado: (2016)

Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer
por: Liu, Shuangjie, et al.
Publicado: (2022)

Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic Cancer
por: Yu, Min, et al.
Publicado: (2019)

Non‐metabolic function of MTHFD2 activates CDK2 in bladder cancer
por: Liu, Xi, et al.
Publicado: (2021)

Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Oral Squamous Cell Carcinoma
por: Cao, Ruoyan, et al.
Publicado: (2020)

Immunological significance of alternative splicing prognostic signatures for bladder cancer
por: Li, Xinyun, et al.
Publicado: (2022)

Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma
por: Wang, Minjie, et al.
Publicado: (2021)

Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer
por: Liu, Mian, et al.
Publicado: (2021)

A Novel Prognostic Signature Based on Ferroptosis-Related Genes Predicts the Prognosis of Patients With Advanced Bladder Urothelial Carcinoma
por: Li, Xiaoqi, et al.
Publicado: (2021)

Identification of prognostic and bone metastatic alternative splicing signatures in bladder cancer
por: Huang, Runzhi, et al.
Publicado: (2021)

Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer
por: Chen, Jiang, et al.
Publicado: (2022)

USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer
por: Man, Xiaojun, et al.
Publicado: (2019)

Identification and Validation of Novel Immune-Related Alternative Splicing Signatures as a Prognostic Model for Colon Cancer
por: Liu, Yunze, et al.
Publicado: (2022)

Development of a Prognostic Alternative Splicing Signature Associated With Tumor Microenvironment Immune Profiles in Lung Adenocarcinoma
por: Bao, Guangyao, et al.
Publicado: (2022)

Alternative splicing event associated with immunological features in bladder cancer
por: Yu, Xinbo, et al.
Publicado: (2023)

Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma
por: Chang, Ya-Sian, et al.
Publicado: (2020)

Correction to: USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer
por: Man, Xiaojun, et al.
Publicado: (2021)

METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
por: Liu, Zhuonan, et al.
Publicado: (2021)

METTL14-mediated N(6)-methyladenosine modification of ITGB4 mRNA inhibits metastasis of clear cell renal cell carcinoma
por: Liu, Zhuonan, et al.
Publicado: (2022)

Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma
por: Sun, Jian-Rong, et al.
Publicado: (2020)

Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder
por: Li, Yu, et al.
Publicado: (2021)

Systematic Analysis of Survival-Associated Alternative Splicing Signatures in Thyroid Carcinoma
por: Han, Baoai, et al.
Publicado: (2021)

miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression
por: Cui, Xiaolu, et al.
Publicado: (2016)

Inhibition of stearoyl CoA desaturase‐1 activity suppresses tumour progression and improves prognosis in human bladder cancer
por: Piao, Chiyuan, et al.
Publicado: (2018)

Bladder melanosis with concurrent urothelial carcinoma
por: Yau, Susanna E., et al.
Publicado: (2017)

Cutaneous metastasis of bladder urothelial carcinoma
por: Hasan, Osamah, et al.
Publicado: (2019)

Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma
por: Liu, Yang, et al.
Publicado: (2020)

Systematic Profiling of Alternative mRNA Splicing Signature for Predicting Glioblastoma Prognosis
por: Chen, Xueran, et al.
Publicado: (2019)

Significant Prognostic Value of the Autophagy-Related Gene P4HB in Bladder Urothelial Carcinoma
por: Lyu, Lei, et al.
Publicado: (2020)

Prognostic Alternative Splicing Signatures in Esophageal Carcinoma
por: Dlamini, Zodwa, et al.
Publicado: (2021)

A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer
por: Fu, Yang, et al.
Publicado: (2021)

Penile metastasis secondary to urothelial bladder cancer
por: Dolny, Maciej, et al.
Publicado: (2023)

Analysis of Prognostic Alternative Splicing Reveals the Landscape of Immune Microenvironment in Thyroid Cancer
por: Wu, Jian, et al.
Publicado: (2021)

The Sigma‐2 Receptor/TMEM97 Agonist PB28 Suppresses Cell Proliferation and Invasion by Regulating the PI3K‐AKT‐mTOR Signalling Pathway in Renal Cancer
por: Zhan, Bo, et al.
Publicado: (2021)

Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma
por: Lin, Zijing, et al.
Publicado: (2021)

A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma
por: Zhu, Liping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4t194fi6hfjpvbr4tfrdknc5o2